


WHAT gBRCA MUTATIONS ACCOUNT FOR



References: **6.** Meynard G, Villanueva C, Thiery-Vuillemin A, et al. 284P—Real-life study of BRCA genetic screening in metastatic breast cancer. *Ann Oncol.* 2017;28(suppl 5):v74-v108. **7.** Fasching PA, Hu C, Hart SN, et al. Cancer predisposition genes in metastatic breast cancer—association with metastatic pattern, prognosis, patient and tumor characteristics. Paper presented at 40th Annual San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, TX. Abstract PD1-02. **8.** Nelson HD, Fu R, Goddard K, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review To Update the U.S. Preventive Services Task Force Recommendation. Rockville, MD: Agency for Healthcare Research and Quality; December 2013. Evidence Synthesis, No. 101; AHRQ publication 12-05164-EF-1. **9.** Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. *J Clin Oncol.* 2016;34(13):1460-1468. **10.** Giordano SH. Breast cancer in men. *N Engl J Med.* 2018;378(24):2311-2320. **11.** Arpino G, Pensabene M, Condello C, et al. Tumor characteristics and prognosis in familial breast cancer. *BMC Cancer.* 2016;16(1):924. **12.** Kleibl Z, Kristensen VN. Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. *Breast.* 2016;28:136-144.